Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...

Schrodinger reported strong Q4 2023 results, but weak guidance for 2024, causing a significant drop in the share price. The demand environment continues to impact the software business, with growth ...

Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...

Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug ‌designing software. Integration of Lilly's ...

All attention is focused on Wednesday, February 25, when Schrodinger is scheduled to release its fourth-quarter and full-year 2025 financial figures after the U.S. market closes. The report will be ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...

Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded Schrödinger, Inc. (NASDAQ:SDGR) from Neutral to Buy, with a $24 price ...

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software ...

Mr. Aklian joins Schrödinger from Certara, where he served as senior vice president, global software sales. In this role, Mr. Aklian led a global team of professionals in sales and operations and ...